News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News Longer-Term ASCVD Risk Assessment Best for Younger Patients Michael O'Riordan February 16, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Daily News ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly L.A. McKeown December 22, 2022
News Daily News A Simple Nudge Moves the Needle on Statin Prescribing Michael O'Riordan December 02, 2022
News Daily News Many ESC Guideline Recommendations Out of Reach in Poorer Regions Michael O'Riordan November 29, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Daily News New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill Shelley Wood August 23, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Daily News USPSTF Recommends Behavior Counseling to Improve Diet and Exercise Habits Michael O'Riordan July 27, 2022
News Daily News ‘Code Blue’ for the Dire CVD Health Status of Most US Adults Michael O'Riordan July 05, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV Michael O'Riordan May 09, 2022